← All Sponsors
SPONSOR

Blueprint Medicines Corporation

Total Trials
2
Recruiting
2
Phases
Phase 2, Phase 3, Phase 4
Conditions studied: Indolent Systemic MastocytosisSmoldering Systemic MastocytosisMastocytosis, Systemic
NCT04910685 Phase 2, Phase 3
Recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Indolent Systemic Mastocytosis
United States, Australia, Austria View Trial →
NCT06748001 Phase 4
Recruiting

Avapritinib Rollover Study

Mastocytosis, Systemic
Belgium, Canada, Italy View Trial →